| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Ocuphire Pharma Inc (NASDAQ: OCUP)
OCUP Technical Analysis
3
| As on 9th Jun 2023 OCUP STOCK Price closed @ 3.76 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.63 & Buy for SHORT-TERM with Stoploss of 3.42 we also expect STOCK to react on Following IMPORTANT LEVELS. |
OCUPSTOCK Price
| Open | 3.95 | Change | Price | % |
| High | 4.04 | 1 Day | -0.20 | -5.05 |
| Low | 3.76 | 1 Week | -0.13 | -3.34 |
| Close | 3.76 | 1 Month | -1.18 | -23.89 |
| Volume | 163480 | 1 Year | 0.02 | 0.53 |
| 52 Week High 6.38 | 52 Week Low 1.80 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| OCUP Daily Charts |
OCUP Intraday Charts |
Whats New @ Bazaartrend |
OCUP Free Analysis |
|
|
OCUP Important Levels Intraday
| RESISTANCE | 4.30 |
| RESISTANCE | 4.13 |
| RESISTANCE | 4.02 |
| RESISTANCE | 3.91 |
| SUPPORT | 3.61 |
| SUPPORT | 3.50 |
| SUPPORT | 3.39 |
| SUPPORT | 3.22 |
OCUP Forecast May 2024
| 4th UP Forecast | 6.32 |
| 3rd UP Forecast | 5.5 |
| 2nd UP Forecast | 4.99 |
| 1st UP Forecast | 4.48 |
| 1st DOWN Forecast | 3.04 |
| 2nd DOWN Forecast | 2.53 |
| 3rd DOWN Forecast | 2.02 |
| 4th DOWN Forecast | 1.2 |
OCUP Weekly Forecast
| 4th UP Forecast | 4.55 |
| 3rd UP Forecast | 4.30 |
| 2nd UP Forecast | 4.14 |
| 1st UP Forecast | 3.98 |
| 1st DOWN Forecast | 3.54 |
| 2nd DOWN Forecast | 3.38 |
| 3rd DOWN Forecast | 3.22 |
| 4th DOWN Forecast | 2.97 |
OCUP Forecast2024
| 4th UP Forecast | 13.05 |
| 3rd UP Forecast | 10.07 |
| 2nd UP Forecast | 8.23 |
| 1st UP Forecast | 6.39 |
| 1st DOWN Forecast | 1.13 |
| 2nd DOWN Forecast | -0.71 |
| 3rd DOWN Forecast | -2.55 |
| 4th DOWN Forecast | -5.53 |
Ocuphire Pharma Inc ( NASDAQ USA Symbol : OCUP )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
OCUP Business Profile
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan. Address: 37000 Grand River Avenue, Farmington Hills, MI, United States, 48335
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service